1134188-71-8

Oxcarbazepine-d₄ is intended for use as an internal standard for the quantification of oxcarbazepine by GC- or LC-MS. Oxcarbazepine is a prodrug form of the antiepileptic compound 10,11-dihydro-10-hydroxy carbamazepine . It inhibits high-frequency repetitive firing of rat spinal cord neurons when used at a concentration of 1 μM. Oxcarbazepine protects against electroshock-induced tonic hindlimb extension (ED₅₀s = 10-20 mg/kg), as well as seizures induced by pentylenetetrazole (PTZ; ) or picrotoxin in rodents (ED₅₀s = 23-30 and 150-250 mg/kg, respectively). Formulations containing oxcarbazepine have been used in the treatment of epileptic seizures.

Oxcarbazepine-d4-1 is deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker[1]. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines[2]. Anti-cancer and anticonvulsant effects[2][3].

[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Ashley M Thomas, et al. Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication ManagementJ Pain. 2018 Jan;19(1):1-9. DOI:10.1016/j.jpain.2017.08.001
[3] Ching-Yi Lee,et al. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016 May;127(3):445-53. DOI:10.1007/s11060-016-2056-6
[4] M Schmutz, et al. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia. 1994;35 Suppl 5:S47-50. DOI:10.1111/j.1528-1157.1994.tb05967.x